Conventional imaging and Multiparametric Magnetic Resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 4, 2012, Pages 331-342

  Panebianco, V ^a   Sciarra, A ^a   Marcantonio, A ^a   Forte, V ^a   Biondi, T ^a   Laghi, A ^a   Catalano, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Diffusion magnetic resonance imaging; Magnetic resonance imaging; Magnetic resonance spectroscopy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANGIOGENESIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869742121     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European Association of Urology. Eur Urol 2011;59:61-71.
2. Walz J, Burnett AL, Costello AJ, Eastham JA, Graefen M, Guillonneau B et al. A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol 2010;57:179-92.
3. Sciarra A, Panebianco V, Salciccia S, Cattarino S, Lisi D, Gentilucci A et al. Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol 2011;1:12-20.
4. Ciccariello M, Teodonio S. Background strumentale nell'imaging della prostata. In: Passariello R, Di Silverio F, Panebianco V, Sciarra A, editors. Imaging RM (risonanza magnetica) della prostata. Milano: Springer-Verlag Italia; 2009. p. 17-24.
5. Lee F Jr, Bronson JP, Lee F, Torp-Pedersen ST, Siders DB, Thornbury JR et al. Non-palpable cancer of the prostate: assessment with transrectal ultrasound. Radiology 1991;178:197-9.
6. Lee F, Torp-Pedersen ST, Siders DB. Use of transrectal ultrasound in diagnosis, guided biopsy, staging, and screening of prostate cancer. Urology 1989;33(Suppl):7-12. (Pubitemid 19158388)
7. Lee F, Torp-Pedersen ST, Siders DB Littrup PJ, McLeary RD. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 1989;170(3 pt 1):609-15. (Pubitemid 19062568)
8. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Bass RB Jr et al. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 1988;139:758-61.
9. Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;152(5 Pt 1):1520-5. (Pubitemid 24326300)
10. Gustafsson O, Norming U, Almgård LE, Fredriksson A, Gustavsson G, Harvig B et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol 1992;148:1827-31.
11. Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ et al. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996;77:150-9.
12. Jones WT, Resnick MI. Prostate ultrasound in screening, diagnosis and staging of prostate cancer. Probl Urol 1999;04:343-57.
13. Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results and potential applications of color Doppler scanning. Radiology 1993;186:509-13. (Pubitemid 23033881)
14. Kelly IM, Lees WR, Rickards D. Prostate cancer and the role of color Doppler ultrasound. Radiology 1933;189:153-6.
15. Uemura H, Sano F, Nomiya A, Yamamoto T, Nakamura M, Miyoshi Y et al. Usefulness of perflubutane microbubble-enhanced ultrasound in imaging and detection of prostate cancer: phase II multicenter clinical trial. World J Urol 2012 [Epub ahead of print].
16. Kapoor A, Kapoor A, Mahajan G, Sidhu BS. Real-time elastography in the detection of prostate cancer in patients with raised PSA level. Ultrasound Med Biol 2011;37:1374-81.
17. Cardone G, Messina A, Borrone M. RM della prostata: aspetti tecnici e protocolli In: Passariello R, Di Silverio F, Panebianco V, Sciarra A, editors. Imaging RM (risonanza magnetica) della prostata. Milano: Springer-Verlag Italia; 2009. p. 25-34.
18. Jacobs MA, Ouwerkerk R, Petrowski K, Macura KJ. Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. Top Magn Reson Imaging 2008;19:261-72.
19. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MR imaging of the prostate in clinical practice. MAGMA 2008;21:379-92.
20. Somford DM, Futterer JJ, Hambrock T, Barentsz JO. Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am 2008;16:685-95, ix.
21. Futterer JJ, Barentsz J, Heijmijnk ST. Imaging modalities for prostate cancer. Expert Rev Anticancer Ther 2009;9:923-37.
22. Yakar D, Debats OA, Bomers JG, Schouten MG, Vos PC, van Lin E et al. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging 2012;35:20-31.
23. Cornud F, Delongchamps NB, Mozer P, Beuvon F, Schull A, Muradyan N et al. Value of multiparametric MRI in the work-up of prostate cancer. Curr Urol Rep 2012;13:82-92.
24. Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009;55:801-14.
25. Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005;236:545-53. (Pubitemid 41023438)
26. Sciarra A, Panebianco V, Salciccia S, Lisi D, Alfarone A, Gentilucci A et al. Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR). Urol Oncol 2011 [Epub ahead of print].
27. 1H-MRSI. Magn Reson Imaging 2012;30:195-204
28. Petralia G, Giannarini G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate and bladder cancer: a critical analysis of the literature. Eur Urol 2012;61:326-40.
29. Metens T, Miranda D, Absil J, Matos C. What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T? Eur Radiol 2012;22:703-9.
30. Franiel T, Hamm B, Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol 2011;21:616-26.
31. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009;30:327-34.
32. Riches SF, Payne GS, Morgan VA, Sandhu S, Fisher C, Germuska M et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol 2009;193:1583-91.
33. Kozlowski P, Chang SD, Meng R, Mädler B, Bell R, Jones EC et al. Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T - quantitative correlation with biopsy. Magn Reson Imaging 2010;28:621-8.
34. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010;31:625-31.
35. Cirillo S, Petracchini M, Della Monica P, Gallo T, Tartaglia V, Vestita E et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008;63:871-9.
36. Moradi M, Salcudean SE, Chang SD, Jones EC, Buchan N, Casey RG et al. Multiparametric MRI maps for detection and grading of dominant prostate tumors. J Magn Reson Imaging 2012;35:1403-13.
37. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol 2011;77:340-5.
38. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259:453-61.
39. Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N et al. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol 2008;49:1207-13.
40. Delongchamps NB, Beuvon F, Eiss D, Flam T, Muradyan N, Zerbib M et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis 2011;14:232-7.
41. Viswanath SE, Bloch NB, Chappelow JC, Toth R, Rofsky NM, Genega EM et al. Central gland and peripheral zone prostate tumors have significantly different quantitative imaging signatures on 3 tesla endorectal, in vivo T2-weighted MR imagery. J Magn Reson Imaging 2012 [Epub ahead of print].
42. Vargas HA, Akin O, Franiel T, Goldman DA, Udo K, Touijer KA et al. Normal Central Zone of the Prostate and Central Zone Involvement by Prostate Cancer: Clinical and MR Imaging Implications. Radiology 2012;262:894-902.
43. De la Rosette JJ, Wink MH, Mamoulakis C, Wondergem N, ten Kate FJ, Zwinderman K et al. Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol. J Urol 2009;182:1329-36.
44. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010;16:1875-83.
45. Aydn H, Kzlgöz V, Tatar IG, Damar C, Ugan AR, Paker I et al. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion co-efficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. J Comput Assist Tomogr 2012;36:30-45.
46. Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009;74:1094-9.
47. Zhang J, Hricak H, Shukla-Dave A, Akin O, Ishill NM, Carlino LJ et al. Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology 2009;253:425-34.
48. Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotto CK et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009;251:122-33.
49. Katahira K, Takahara T, Kwee TC, Oda S, Suzuki Y, Morishita S et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol 2011;21:188-96.
50. Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012 [Epub ahead of print].
51. Panebianco V, Sciarra A, De Berardinis E, Busetto G, Lisi D, Buonocore V et al. PCA3 Urinary Test Versus 1H-MRS and DCEMR in the Detection of Prostate Cancer Foci in Patients with Biochemical Alterations. Anticancer Res 2011;31:1399-405.
52. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012 [Epub ahead of print].
53. Kim B, Breau RH, Papadatos D, Fergusson D, Doucette S, Cagiannos I et al. Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5 T for local staging of elevated risk prostate cancer. Can Urol Assoc J 2010;4:257-62.
54. Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol 2009;50:562-9.
55. Labanaris AP, Zugor V, Takriti S, Smiszek R, Engelhard K, Nutzel R et al. The role of conventional and functional endorectal magnetic resonance imaging in the decision of whether to preserve or resect the neurovascular bundles during radical retropubic prostatectomy. Scand J Urol Nephrol 2009;43:25-31.
56. Brown JA, Rodin DM, Harisinghani M, Dahl DM. Impact of preoperative endorectal MRI stage classification on neurovascular bundle sparing aggressiveness and the radical prostatectomy positive margin rate. Urol Oncol 2009;27:174-9.
57. Panebianco V, Sciarra A, Osimani M, Lisi D, Ciccariello M, Salciccia S et al. 2D and 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy with erectile function correlation. Eur Radiol 2009;19:220-9.
58. McClure TD, Margolis DJ, Reiter RE, Sayre JW, Thomas MA, Nagarajan R et al. Use of MR Imaging to Determine Preservation of the Neurovascular Bundles at Robotic-assisted Laparoscopic Prostatectomy. Radiology 2012;262:874-83.
59. Naiki T, Okamura T, Nagata D, Mori Y, Kawai N, Ogawa K et al. Preoperative prediction of neurovascular bundle involvement of localized prostate cancer by combined T2 and diffusion-weighted imaging of magnetic resonance imaging, number of positive biopsy cores, and Gleason score. Asian Pac J Cancer Prev 2011;12:909-13.
60. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63:387-95.
61. Ketelsen D, Röthke M, Aschoff P, Merseburger AS, Lichy MP, Reimold M et al. [Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy]. Rofo 2008;180:746-52.
62. Gutzeit A, Doert A, Froehlich JM, Eckhardt BP, Meili A, Scherr P et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010;39:333-43.
63. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19:761-9.
64. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54:589-600.
65. Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F] choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2011 [Epub ahead of print].
66. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA et al. Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer. Radiology 2011;259:453-61.